There were 347 press releases posted in the last 24 hours and 216,008 in the last 365 days.

Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

The majority of the drugs for Corneal Ulcer are in the early stages of development and in coming years the market is expected to grow. 

/EIN News/ -- Los Angeles, June 10, 2021 (GLOBE NEWSWIRE) -- Corneal Ulcer Pipeline Analysis Demonstrates Novel Therapies at the Horizon Expected to Transform the Treatment Paradigm | DelveInsight

The majority of the drugs for Corneal Ulcer are in the early stages of development and in coming years the market is expected to grow. 

DelveInsight’s Corneal Ulcer Pipeline Insights report provides the current treatment landscape and rich analysis of pipeline therapies in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. 

Some of the key pointers from the Corneal Ulcer Pipeline report:

  • Corneal Ulcer Pipeline report offers a rich analysis of  6+ key pharma companies and 6+ key therapies. 
  • Corneal Ulcer pipeline comprises therapies in different stages of trials such as SREC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium, among others. 
  • Key pharma companies working to make the Corneal Ulcer pipeline robust include Recordati/Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, among others. 
  • FDA granted Orphan Drug Designation to Recordati Rare Diseases investigational product REC 0559 for the treatment of neurotrophic keratitis.

Discover more about the pharma company and therapy expected to grab maximum share by requesting sample report @ Corneal Ulcer Emerging Therapies and Forecast 

Corneal Ulcer: Overview

Corneal Ulcer, also known as Keratitis, is characterized by damage or loss of the epithelial layer associated with infiltration of the underlying corneal stroma. 

Whilst the treatment of refractory corneal ulcers is challenging, it is essential that they are resolved as they can quickly endanger the anatomical integrity of the ocular surface or the transparency of the cornea.

Discover more about disease outlook, available therapies, and emerging drugs, visit Corneal Ulcer Pipeline Analysis 

Corneal Ulcer Drug Pipeline Assessment

Drug Company Phase MoA RoA
REC 0559 Recordati/Mime Tech Phase II Apoptosis inhibitors; Autophagy inhibitors; Nerve growth factor receptor agonists Eye drop solution
OC01 Oyster Point Pharma Preclinical Alpha4 beta2 nicotinic receptor agonists NA
CSB-001 Claris Biotherapeutics Phase I/II NA Ophthalmic Solution 
BD-111 Shanghai BDgene Phase I/II Undefined mechanism corneal injection
NRO-1 Neuroptika Phase I Glial cell line-derived neurotrophic factor agonists Topical
Rose bengal sodium Provectus Biopharmaceuticals Preclinical Cell death stimulants; Cell membrane modulators; Dendritic cell stimulants; Immunostimulants; Interferon modulators; Interleukin 17 modulators; Interleukin-22 modulators Topical

Request for Sample to know more @ Corneal Ulcer Pipeline Analysis, Key Companies, and Futuristic Trends 

Corneal Ulcer Therapeutics Assessment 

The Corneal Ulcer Pipeline report lays down a comprehensive coverage of the active pipeline candidates segmented by Stage, Product Type, Route of Administration (RoA), Molecule Type, Target, and Mechanism of Action (MoA).

By Product Type

  • Mono
  • Combination

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Molecule Type 

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

By Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

By Mechanism of Action

  • Nerve growth factor receptor agonists
  • Glial cell line-derived neurotrophic factor agonists
  • Alpha4 beta2 nicotinic receptor agonists
  • Autophagy inhibitors
  • Cell membrane modulators
  • Autophagy inhibitors

By Targets

  • Nerve growth factor receptor
  • Glial cell line-derived neurotrophic factor
  • Alpha4 beta2 nicotinic receptor

Connect with our Business Executive for Asset Prioritization Services and Consulting Solutions 

Scope of the Corneal Ulcer Pipeline Report

Coverage: Global
Key Players: Recordati/Mime Tech, Oyster Point Pharma, Claris Biotherapeutics, Shanghai BDgene, Neuroptika, Provectus Biopharmaceuticals, OcuNexus Therapeutics, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc., Dobecure, Editas medicine, and others. 
Key Corneal Ulcer Pipeline Therapies: REC 0559, OC01, CSB-001, BD-111, NRO-1, Rose bengal sodium, and others. 

Reach out @ Corneal Ulcer Pipeline: Novel therapies and Emerging technologies 

Table of Contents 

1 Report Introduction
2 Corneal Ulcer Disease Overview
3 Corneal Ulcer Pipeline Therapeutics
4 Therapeutic Assessment
5 Corneal Ulcer – DelveInsight’s Analytical Perspective
6 In-depth Commercial Assessment
7 Corneal Ulcer Collaboration Deals
8 Corneal Ulcer Therapeutic Products in Clinical Stage
9 Corneal Ulcer Therapeutic Products in Non-clinical Stage
10 Corneal Ulcer Therapeutics Pipeline Analysis
11 Inactive Corneal Ulcer Pipeline Products 
12 Corneal Ulcer Key Companies
13 Corneal Ulcer Key Products
14 Corneal Ulcer- Unmet Needs
15 Corneal Ulcer Market Drivers and Barriers
16 Corneal Ulcer- Future Perspectives and Conclusion
17 Corneal Ulcer Analyst Views
18 Appendix
19  Report Methodology
20 Consulting Services
21 Disclaimer
22 About DelveInsight

Learn more about the report offerings @ Corneal Ulcer Emerging Therapies, Treatments and Ongoing Clinical Trials 

Related Reports
Corneal Ulcer Market
DelveInsight's "Corneal Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report.
Peptic Ulcer Hemorrhage Market
DelveInsight's "Peptic Ulcer Hemorrhage - Market Insights, Epidemiology, and Market Forecast-2030" report.
Varicose Ulcer Market
DelveInsight's " Varicose Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report. 
Venous Leg Ulcer Market
DelveInsight's "Venous Leg Ulcer - Market Insights, Epidemiology, and Market Forecast-2030" report.

Related Posts 
Global Burden of Cytomegalovirus Seroprevalence
Analysis of therapies and key companies such as Merck, Helocyte, Shire, Atara Biotherapeutics, ViraCyte, and others.  

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 


 
Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com

Primary Logo